Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps

Alcohol use disorder (AUD) imposes a significant mortality and health care cost burden in the United States, resulting in an estimated 178,307 deaths annually during 2020-2021, representing an approximate 29.3% increase from 2016-2017.¹ AUD is also associated with substantial health care expenditures and productivity losses nationwide, with alcohol-associated liver disease alone representing approximately $31 billion in US health care costs in 2022.² Existing pharmacotherapies, including naltrexone, acamprosate, disulfiram, and gabapentinoids, have reduced alcohol consumption for some patients but have not consistently achieved sustained abstinence across more extensive populations.^3,4 This persistent treatment gap has prompted renewed investigation into psilocybin-assisted therapy, particularly for those who have not responded to standard pharmacologic and psychosocial interventions.

Mechanism of Action

Following ingestion, psilocybin is metabolized to psilocin, which primarily targets 5-HT_2A receptors and influences 5-HT_1A receptors. These receptor interactions are associated with altered neural network connectivity, amplified emotional processing, and neuroplastic changes involving glutamate, brain-derived neurotrophic factor, tropomyosin receptor kinase B, and mTOR pathways.^5,6 The neurobiological model of psilocybin-assisted therapy in AUD now encompasses mechanisms of transcriptional and network-level plasticity in addition to receptor pharmacology.^7,8

Clinical Trial Evidence

The most robust findings in AUD research center on reductions in heavy-drinking days. In the largest randomized controlled trial to date, Bogenschutz et al enrolled 95 adults with moderate or severe AUD and compared psilocybin-assisted psychotherapy with diphenhydramine-assisted psychotherapy.⁹ Over a 32-week period, the psilocybin group exhibited a lower percentage of heavy-drinking days (9.7%) compared with the control group (23.6%), suggesting that psilocybin-assisted therapy may reduce harmful drinking even in the absence of complete abstinence.⁹

Earlier proof-of-concept studies support this trend. In another study, Bogenschutz et al treated 10 adults with alcohol dependence using motivational enhancement therapy combined with 2 psilocybin sessions. Heavy-drinking days decreased from approximately 54% at baseline to 10% during follow-up, with a substantial increase in abstinent days. Although this study did not include a control group, the sustained improvement over 36 weeks provided a rationale for subsequent randomized trials.¹⁰

Further, Jensen et al reported findings from a 2025 open-label feasibility study involving 10 adults with severe AUD who received a single 25-mg psilocybin session combined with psychotherapy. Over 12 weeks, heavy-drinking days decreased by 37.5 percentage points, and the average number of drinks per day declined. These outcomes suggest potential efficacy for single-dose models, although the small sample size and absence of a comparator group limit causal interpretation.¹¹

Luquiens et al provided randomized feasibility data among recently detoxified adults with AUD and comorbid depressive symptoms. Participants received either two 25-mg psilocybin sessions or a low-dose 1-mg psilocybin control. At 12 weeks, 55% of the high-dose group achieved abstinence compared with 11% of the control group, and drinking-day outcomes also favored the 25-mg group.¹² These data suggest that psilocybin may facilitate early recovery following detoxification, although larger studies are required to confirm these effects.¹²

Rieser et al reported more cautious findings in a phase 2 relapse-prevention trial. Participants who received a single 25-mg psilocybin session did not reveal a statistically significant advantage in abstinent days at the 4-week primary end point compared with a placebo. This result suggests that psilocybin outcomes may depend on dosing schedule, psychotherapy structure, follow-up duration, patient characteristics, and outcome measures.¹³

Safety and Implementation Considerations

Heinzerling et al introduced important implementation and safety considerations in a 2023 pilot randomized trial.¹⁴ In that study, 20 adults with AUD received 2 open-label 25-mg psilocybin sessions and were randomly assigned to either a nature-themed “visual healing” environment or standard set-and-setting procedures. Nineteen participants completed the 14-week study. Alcohol use decreased in both groups, and the nature video group had a significantly lower blood pressure increase during the first dosing session.¹⁴ Although placebo-controlled efficacy was not established, this evidence suggests therapeutic-environment modification might improve cardiovascular safety without worsening alcohol-related outcomes.

Health Care Implications

Psilocybin-assisted therapy has demonstrated its most consistent effect in reducing heavy-drinking days, whereas findings regarding sustained abstinence have been less consistent across studies. In controlled clinical settings, the therapy exhibits a favorable safety profile, with transient anxiety, headache, nausea, and blood pressure elevations as the most common adverse effects (Table).^9-12,14,15 Nevertheless, the current evidence base is limited by small sample sizes, incomplete blinding, homogeneous participant populations, and short follow-up periods, which constrain generalizability. Establishing psilocybin-assisted therapy as a standard treatment for AUD will require larger multisite trials with heterogeneous groups, standardized psychotherapeutic frameworks, active comparators, longer-term outcomes, and careful safety monitoring.

Emerging evidence indicates that psilocybin-assisted therapy may also address psychological drivers of AUD. Reported reductions in alcohol craving and alcohol-cue reactivity suggest that its therapeutic effects could extend beyond drinking behavior, potentially supporting cognitive and affective restructuring during recovery.^15,16

Psilocybin-assisted therapy has demonstrated preliminary clinical benefit for AUD, including reductions in heavy-drinking days in randomized trials, but implementation calls for careful patient screening, cardiovascular monitoring, trained clinical teams, and controlled treatment settings.¹⁷ From a health care perspective, scalable delivery models may reduce costs. Group psychedelic-therapy protocols are estimated to lower clinician costs by 34.7%, or $981 per patient, for psilocybin-based care. Recent modeling suggests psilocybin-assisted therapy could save approximately $7000 per patient and add 0.10 quality-adjusted life-years compared with standard care in treatment-resistant depression.^18,19

Health care systems considering psilocybin trials require targeted investment in trained clinicians and supervised treatment spaces. However, group-delivery models may reduce clinician costs and decrease workforce demand by 1159 full-time-equivalent clinicians over 10 years for psilocybin-based care models.¹⁸

REFERENCES

1. Esser MB, Sherk A, Liu Y, Naimi TS. Deaths from excessive alcohol use - United States, 2016-2021. MMWR Morb Mortal Wkly Rep. 2024;73(8):154-161. doi:10.15585/mmwr.mm7308a1

2. Julien J, Ayer T, Tapper EB, Chhatwal J. The rising costs of alcohol-associated liver disease in the United States. Am J Gastroenterol. 2024;119(2):270-277. doi:10.14309/ajg.0000000000002405

3. Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815-824. doi:10.1001/jama.2018.11406

4. Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv. 2019;5(9):eaax4043. doi:10.1126/sciadv.aax4043

5. Urban MM, Stingl MR, Meinhardt MW. Mini-review: the neurobiology of treating substance use disorders with classical psychedelics. Front Neurosci. 2023;17:1156319. doi:10.3389/fnins.2023.1156319

6. Gattuso JJ, Wilson C, Hannan AJ, Renoir T. Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: a systematic review. J Neurochem. 2024;168(9):1687-1720. doi:10.1111/jnc.16017

7. Erkizia-Santamaría I, Alles-Pascual R, Horrillo I, Meana JJ, Ortega JE. Serotonin 5-HT_2A, 5-HT_2C and 5-HT_1A receptor involvement in the acute effects of psilocybin in mice: in vitro pharmacological profile and modulation of thermoregulation and head-twitch response. Biomed Pharmacother. 2022;154:113612. doi:10.1016/j.biopha.2022.113612

8. Lerer E, Botvinnik A, Shahar O, et al. Effects of psilocybin, psychedelic mushroom extract and 5-hydroxytryptophan on brain immediate early gene expression: interaction with serotonergic receptor modulators. Front Pharmacol. 2024;15:1391412. doi:10.3389/fphar.2024.1391412

9. Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79(10):953-962. doi:10.1001/jamapsychiatry.2022.2096

10. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289-299. doi:10.1177/0269881114565144

11. Jensen ME, Stenbaek DS, Messell CD, et al. Single-dose psilocybin therapy for alcohol use disorder: pharmacokinetics, feasibility, safety, and efficacy in an open-label study. J Psychopharmacol. 2025;39(5):463-473. doi:10.1177/02698811251319457

12. Luquiens A, Belahda D, Graux C, et al. Psilocybin in alcohol use disorder and comorbid depressive symptoms: results from a feasibility randomized clinical trial. Addiction. Published online July 24, 2025. doi:10.1111/add.70152

13. Rieser NM, Bitar R, Halm S, et al. Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. EClinicalMedicine. 2025;82:103149. doi:10.1016/j.eclinm.2025.103149

14. Heinzerling KG, Sergi K, Linton M, et al. Nature-themed video intervention may improve the cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder. Front Psychiatry. 2023;14:1215972. doi:10.3389/fpsyt.2023.1215972

15. Pagni BA, Petridis PD, Podrebarac SK, Grinband J, Claus ED, Bogenschutz MP. Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study. Sci Rep. 2024;14(1):3159. doi:10.1038/s41598-024-52967-8

16. Agin-Liebes G, Nielson EM, Zingman M, et al. Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: an interpretive phenomenological analysis. Psychol Addict Behav. 2024;38(1):101-113. doi:10.1037/adb0000935

17. Pronovost-Morgan C, Greenway KT, Roseman L; ReSPCT Experts. An international Delphi consensus for reporting of setting in psychedelic clinical trials. Nat Med. 2025;31(7):2186-2195. doi:10.1038/s41591-025-03685-9

18. Marseille E, Stauffer CS, Agrawal M, et al. Group psychedelic therapy: empirical estimates of cost-savings and improved access. Front Psychiatry. 2023;14:1293243. doi:10.3389/fpsyt.2023.1293243

19. Ziadi Y, Park T. Cost-effectiveness of psilocybin-assisted therapy versus standard of care for patients with treatment-resistant depression. Value Health Reg Issues. Published online March 17, 2026. doi:10.1016/j.vhri.2026.101605